PAVmed (NASDAQ:PAVM) Stock Price Passes Below Fifty Day Moving Average – Should You Sell?

PAVmed Inc. (NASDAQ:PAVM) crossed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $8.72 and traded as low as $6.11. PAVmed shares last traded at $6.39, with a volume of 6,460 shares trading hands.

Wall Street Analyst Weigh In

PAVM has been the subject of several recent research reports. Weiss Ratings reissued a “sell (d)” rating on shares of PAVmed in a research report on Tuesday, April 21st. Ascendiant Capital Markets dropped their price objective on PAVmed from $510.00 to $65.00 and set a “buy” rating on the stock in a research note on Thursday, April 9th. Finally, Wall Street Zen upgraded PAVmed from a “sell” rating to a “hold” rating in a research note on Saturday, April 4th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $65.00.

PAVmed Stock Performance

The company has a market cap of $6.39 million, a P/E ratio of -0.17 and a beta of 0.64. The company has a quick ratio of 2.02, a current ratio of 2.02 and a debt-to-equity ratio of 0.70. The stock has a 50 day moving average price of $8.72 and a two-hundred day moving average price of $9.30.

PAVmed (NASDAQ:PAVM) last announced its earnings results on Friday, May 15th. The company reported ($1.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.48). The firm had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.07 million. PAVmed had a negative return on equity of 146.19% and a negative net margin of 21,914.12%. On average, research analysts predict that PAVmed Inc. will post -3.19 earnings per share for the current fiscal year.

Hedge Funds Weigh In On PAVmed

An institutional investor recently raised its position in PAVmed stock. Jane Street Group LLC lifted its position in shares of PAVmed Inc. (NASDAQ:PAVM) by 392.9% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 52,676 shares of the company’s stock after purchasing an additional 41,990 shares during the period. Jane Street Group LLC owned 0.31% of PAVmed worth $32,000 as of its most recent filing with the Securities and Exchange Commission. 19.93% of the stock is currently owned by institutional investors.

PAVmed Company Profile

PAVmed Inc is a clinical-stage medical technology company focused on acquiring, developing and commercializing innovative medical devices aimed primarily at gastrointestinal endoscopy and related therapeutic areas. Its portfolio includes FDA-cleared products such as EsoFLIP® Distensibility System for the treatment of esophageal strictures and MUSE™ (Medigus Ultrasonic Surgical Endostapler) for endoscopic fundoplication in gastroesophageal reflux disease (GERD). In addition to its gastrointestinal franchise, PAVmed is advancing early-stage programs targeting indications in oncology, urology and dermatology.

Founded in 2012, PAVmed has built its pipeline through internal research and development as well as strategic collaborations and acquisitions.